[{"id":"8219a865-ee1b-4147-b478-9542d52eab59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858310","created_at":"2021-01-18T14:01:47.880Z","updated_at":"2024-07-02T16:34:58.731Z","phase":"Phase 1/2","brief_title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","source_id_and_acronym":"NCT02858310","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 01/27/2017","start_date":" 01/27/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-05"},{"id":"cd9c68a8-062c-418a-8a7a-3f467abc3209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05639972","created_at":"2022-12-07T16:57:48.136Z","updated_at":"2024-07-02T16:35:33.860Z","phase":"Phase 1/2","brief_title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","source_id_and_acronym":"NCT05639972","lead_sponsor":"Christian Hinrichs","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • E7 TCR cells • E7 TCR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-11"},{"id":"81299e80-d031-4a6e-a4ba-57495996a748","acronym":"","url":"https://clinicaltrials.gov/study/NCT04044950","created_at":"2021-06-30T14:53:45.767Z","updated_at":"2024-07-02T16:36:40.811Z","phase":"Phase 2","brief_title":"A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer","source_id_and_acronym":"NCT04044950","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7 TCR cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 09/17/2020","primary_completion_date":" 09/17/2020","study_txt":" Completion: 09/17/2020","study_completion_date":" 09/17/2020","last_update_posted":"2020-09-22"}]